CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 10,154 enrolled
Drug / intervention
Dietary Supplement/Vitamins +1 moredrug
Likely dose
Vitamin C 1000 mg + Vitamin E 400 IU orally, two capsules daily from 9-16 weeks gestation through deliveryAI-extracted
Key inclusion· 3
  • Gestational age 9-16 weeks at randomization
  • Singleton pregnancy
  • Nulliparous (no prior deliveries)
Key exclusion· 12
  • Blood pressure ≥135/85 mmHg
  • Proteinuria on urinalysis
  • Current or prior use of antihypertensive medications or diuretics
  • Pregestational diabetes (Type 1 or Type 2)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00135707
NCT00135707Phase 3Completed

A Randomized Clinical Trial of Antioxidants to Prevent Preeclampsia and An Observational Cohort Study to Predict Preeclampsia

The George Washington University Biostatistics Center·interventional·Posted Aug 26, 2005·Updated Feb 21, 2019

In Brief

A Phase 3 clinical trial evaluating Dietary Supplement/Vitamins and Placebo for Vitamin C and Vitamin E for Preeclampsia. Completed, enrolled 10,154 participants across 16 sites.

Detailed Summary

Preeclampsia is one of the most common complications of pregnancy and is characterized by high blood pressure and protein in the urine. This can cause problems in the second half of pregnancy for both the mother and fetus. This study of preeclampsia consists of two parts: 1) a randomized, placebo controlled, multicenter clinical trial of 10,000 low-risk nulliparous women between 9 and 16 weeks gestation and 2) an observational, cohort study of 4,000 patients between 9 and 12 weeks gestation who are also enrolled in the trial. Subjects in both parts will receive either 1000 mg of vitamin C and 400 IU of vitamin E or matching placebo daily. The purpose of the randomized, clinical trial is to find out if high doses of vitamin C and E will reduce the risk of preeclampsia and other problems associated with the disease. The study will also evaluate the safety of antioxidant therapy for mother and infant. Patients will be seen monthly to receive their supply of study drug, to have weight and blood pressure recorded, to have urine protein measured, and to assess any side effects. At two visits, blood and urine will be collected. The observational, cohort study will prospectively measure potential biochemical and biophysical markers that might predict preeclampsia. These patients will have additional procedures including uterine artery Doppler and blood drawn for a complete blood count (CBC).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPreeclampsia
CountriesUnited States

Timeline

Phase 3CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 26, 2005
Enrollment StartJun 1, 2003
Primary CompletionOct 1, 2008
Study CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 20.8 years ago

Interventions

Dietary Supplement/Vitaminsdrug

Vitamin C (1000 mg) and Vitamin E (400 IU) per capsule, two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.

Placebo for Vitamin C and Vitamin Edrug

Placebo two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.